Select

Save Up To 85% With This Free Ketek Discount Card!

Click here to request card

Comments (0)

LOG IN WITH
OR PICK A NAME
Your email is safe with us. It is only used for moderation and optional notifications.
Email is incorrect.

Ketek Reviews (0)

Average Rating

Your Star Rating, the more stars the better
LOG IN WITH
OR PICK A NAME
Your email is safe with us. It is only used for moderation and optional notifications.
Email is incorrect.

Ketek Prescribing Information

This information is not for clinical use. These highlights do not include all the information needed to use Ketek safely and effectively. Before taking Ketek please consult with your doctor. See full prescribing information for Ketek.

Warning

WARNING: CONTRAINDICATION IN MYASTHENIA GRAVIS There have been reports of fatal and life-threatening respiratory failure in patients with myasthenia gravis associated with the use of KETEK. [see Contraindications (4.1)] WARNING: CONTRAINDICATION IN MYASTHENIA GRAVIS See full prescribing information for complete boxed warning Fatal and life-threatening respiratory failure has been reported in patients with myasthenia gravis associated with use of KETEK (4.1)

Recent Changes

Warnings and Precautions (5.2) 10/15

Indications And Usage

KETEK is indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae, (including multi-drug resistant S. pneumoniae [MDRSPMDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are isolates resistant to two or more of the following antibacterials: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.]), Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, or Mycoplasma pneumoniae, for patients 18 years or older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. KETEK is a ketolide antibacterial indicated for the treatment of community-acquired pneumonia of mild to moderate severity. (1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1)

Does this card cost me anything?

NO - The Pharmacy Savings Card alone does not cost you anything

Dosage Forms And Strengths

KETEK tablets are available in two strengths: Tablets: 400 mg supplied as light-orange, oval, film-coated tablets, imprinted "H3647" on one side and "400" on the other side. Tablets: 300 mg supplied as light-orange, oval, film-coated tablets, imprinted "38AV" on one side and blank on the other side. Tablets: 300 mg and 400 mg (3)

Contraindications

Patients with myasthenia gravis. (4.1) History of hepatitis or jaundice with KETEK or any macrolide. (4.2) Known hypersensitivity to KETEK or any macrolide. (4.3) Concomitant administration of KETEK with cisapride or pimozide. (4.4) Concomitant administration of KETEK and colchicine in patients with renal or hepatic impairment. (4.5) 4.1 Myasthenia Gravis KETEK is contraindicated in patients with myasthenia gravis. Exacerbations of myasthenia gravis have been reported in patients and sometimes occurred within a few hours of the first dose of KETEK. Reports have included fatal and life-threatening acute respiratory failure with a rapid onset and progression. 4.2 Hepatitis KETEK is contraindicated in patients with previous history of hepatitis and/or jaundice associated with the use of KETEK tablets, or any macrolide antibacterial. [see Warnings and Precautions (5.1)] 4.3 Hypersensitivity KETEK is contraindicated in patients with a history of hypersensitivity to telithromycin, any components of KETEK tablets, or any macrolide antibacterial.[see Description (11)] 4.4 Cisapride/Pimozide Concomitant administration of KETEK with cisapride or pimozide is contraindicated because co-administration can lead to life-threatening QT prolongation. [see Warnings and Precautions (5.2); Drug Interactions (7)] 4.5 Colchicine Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or hepatic impairment due to increased plasma concentration of colchicine leading to life-threatening colchicine toxicity. [see Warnings and Precautions (5.4); Drug Interactions (7)]

Warning and Cautions

Hepatotoxicity: Fatal acute liver injury has been reported. Discontinue immediately if signs and symptoms of hepatitis occur. (5.1) Prolongation of QTc interval: Increased risk for ventricular arrhythmias, including ventricular tachycardia and torsade de pointes with fatal outcomes. Avoid use in patients with known QTc prolongation, hypokalemia, and with class IA and III antiarrhythmics. (5.2) Visual disturbances and loss of consciousness: KETEK may impair accommodation. Avoid driving or other hazardous activity. (5.3) Serious Adverse Reactions with Concomitant Drugs: Fatalities with colchicine, rhabdomyolysis with HMG-CoA reductase inhibitors, and hypotension with calcium channel blockers have been reported. Avoid concomitant use. Monitor for toxicity and consider dose reduction of the concomitant medication, if concomitant use is unavoidable (5.4, 7) Clostridium difficile-associated diarrhea: evaluate if diarrhea occurs. (5.5) 5.1 Hepatotoxicity Acute hepatic failure and severe liver injury, in some cases fatal, have been reported in patients treated with KETEK. These hepatic reactions included fulminant hepatitis and hepatic necrosis leading to liver transplant, and were observed during or immediately after treatment. In some of these cases, liver injury progressed rapidly and occurred after administration of a few doses of KETEK. Physicians and patients should monitor for the appearance of signs or symptoms of hepatitis, such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinuria, alcoholic stools, liver tenderness, or hepatomegaly. Patients with signs or symptoms of hepatitis must be advised to discontinue KETEK and immediately seek medical evaluation, which should include liver function tests. If clinical hepatitis or transaminase elevations combined with other systemic symptoms occur, KETEK should be permanently discontinued. KETEK is contraindicated in patients with a previous history of hepatitis and/or jaundice associated with the use of KETEK tablets, or any macrolide antibacterial. [see Contraindications (4.2)] In addition, less severe hepatic dysfunction associated with increased liver enzymes, hepatitis and in some cases jaundice was reported with the use of KETEK. These events associated with less severe forms of liver toxicity were reversible. 5.2 QTc Prolongation KETEK can prolong the QTc interval of the electrocardiogram in some patients leading to an increased risk for ventricular arrhythmias, including ventricular tachycardia and torsades de pointes with fatal outcomes. Thus, KETEK should be avoided in patients with congenital prolongation of the QTc interval, and in patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (e.g., quinidine and procainamide) or Class III (e.g., dofetilide) antiarrhythmic agents. Cases of ventricular arrhythmias (including ventricular tachycardia and torsades de pointes) have been reported post-marketing with KETEK and sometimes occurred within a few hours of the first dose. In clinical trials, no cardiovascular morbidity or mortality attributable to QTc prolongation occurred with KETEK treatment in 4780 patients, including 204 patients having a prolonged QTc at baseline. 5.3 Visual Disturbances and Loss of Consciousness KETEK may cause visual disturbances particularly in slowing the ability to accommodate and the ability to release accommodation. Visual disturbances, some of them severe, included blurred vision, difficulty focusing, and diplopia. [see Adverse Reactions (6.1)] There have been post-marketing reports of transient loss of consciousness including some cases associated with vagal syndrome. Because of potential visual difficulties or loss of consciousness, patients should attempt to minimize activities such as driving a motor vehicle, operating heavy machinery or engaging in other hazardous activities during treatment with KETEK. If patients experience visual disorders or loss of consciousness while taking KETEK, patients should not drive a motor vehicle, operate heavy machinery or engage in other hazardous activities. 5.4 Serious Adverse Reactions with Concomitant Drugs Serious adverse reactions have been reported in patients taking KETEK concomitantly with CYP3A4 substrates [see Drug Interactions (7)]: Colchicine: colchicine toxicity Simvastatin, lovastatin, and atorvastatin: rhabdomyolysis Calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem): hypotension Colchicine Toxicity Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong CYP3A4 inhibitors. KETEK is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended dosages. If co-administration of KETEK and colchicine is necessary in patients with normal renal and hepatic function, reduce the dosage of colchicine. Monitor patients for clinical symptoms of colchicine toxicity. Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or hepatic impairment. [see Contraindications (4.5); Drug Interactions (7)] Rhabdomyolysis Simvastatin, lovastatin and atorvastatin are metabolized by CYP3A4. High levels of HMG-CoA reductase inhibitors increase the risk of myopathy and rhabdomyolysis. Avoid use of statins which are metabolized by CYP3A4 concomitantly with KETEK; suspend therapy with simvastatin, lovastatin, or atorvastatin during the course of treatment with KETEK. [see Drug Interactions (7)] Hypotension Hypotension, bradyarrhythmia and loss of consciousness have been observed in patients receiving concomitant treatment with calcium channel blockers that are substrates of CYP3A4 (e.g., verapamil, amlodipine, diltiazem). Monitor for these adverse reactions and toxicity related to calcium channel blockers and adjust calcium channel blocker dosage as necessary. [see Drug Interactions (7)] 5.5 Clostridum difficile-Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including KETEK, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. 5.6 Development of Drug Resistant Bacteria Prescribing KETEK in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: Myasthenia gravis [see Contraindications (4.1)] Hepatotoxicity [see Warnings and Precautions (5.1)] QTc prolongation [see Warnings and Precautions (5.2)] Visual disturbances and loss of consciousness [see Warnings and Precautions (5.3)] Clostridium difficile-associated diarrhea [see Warnings and Precautions (5.5)] The most common adverse reactions (2% or greater) are diarrhea, nausea, dizziness, and vomiting (6.1) To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In Phase 3 clinical trials, 4,780 patients (n=2702 in controlled trials) received oral dosages of KETEK 800 mg once daily for 5 days or 7 to 10 days. Note that treatment with KETEK for 5 days duration is not a recommended dosage regimen. [see Dosage and Administration (2.1)] In the combined Phase 3 studies, discontinuation due to adverse reactions occurred in 4.4% of KETEK-treated patients and 4.3% of combined comparator-treated patients. Most discontinuations in the KETEK group were due to adverse reactions in the gastrointestinal body system, primarily diarrhea (0.9% for KETEK vs. 0.7% for comparators), and nausea (0.7% for KETEK vs. 0.5% for comparators). Adverse reactions (ARs) occurring in clinical studies in 2% or more of KETEK patients are included below. Table 1. Adverse Reactions Reported in 2% or more of Patients in Controlled Phase 3 Clinical Studies Adverse ReactionBased on a frequency of all and possibly related adverse reactions of 2% or more in KETEK or comparator groups. Percent Incidence KETEK n= 2702 ComparatorIncludes comparators from all controlled Phase 3 studies. n= 2139 Diarrhea 10% 8% Nausea 7% 4.1% Dizziness (excl. vertigo) 2.8% 1.5% Vomiting 2.4% 1.4% Less Common Adverse Reactions Frequency of 0.2% or more and less than 2% The following adverse reactions were observed at a frequency of 0.2% or more and less than 2% in KETEK-treated patients in clinical studies. Gastrointestinal system: abdominal distension, dyspepsia, gastrointestinal upset, flatulence, constipation, gastroenteritis, gastritis, anorexia, oral candidiasis, glossitis, stomatitis. Liver and biliary system: abnormal liver function tests: increased transaminases (i.e., ALT, AST). Hepatitis, with or without jaundice, occurred in 0.07% of patients treated with KETEK. [see Warnings and Precautions (5.1)] Nervous system: dry mouth, somnolence, insomnia, vertigo, increased sweating Body as a whole: abdominal pain, fatigue Special senses: Visual adverse reactions, some of them severe, most often included blurred vision, diplopia, or difficulty focusing. Some patients discontinued therapy due to these adverse reactions. Visual adverse reactions were reported as having occurred after any dose during treatment, but most (65%) occurred following the first or second dose. Visual adverse reactions lasted several hours and recurred upon subsequent dosing in some patients. For patients who continued treatment, some visual adverse reactions resolved on therapy while others persisted through the full course of treatment. [see Warnings and Precautions (5.3)] Females and patients under 40 years old experienced a higher incidence of KETEK-associated visual adverse reactions. Table 2 provides the incidence of all visual adverse reactions in controlled Phase 3 studies by age and gender. The group with the highest incidence was females under the age of 40, while males over the age of 40 had rates of visual adverse reactions similar to comparator-treated patients. Table 2. Incidence of All Visual Adverse Reactions in Controlled Phase 3 Studies Gender/Age Telithromycin ComparatorsIncludes all comparators combined Female 40 and under 2.1% (14/682) 0.0% (0/534) Female greater than 40 1.0% (7/703) 0.35% (2/574) Male 40 and under 1.2% (7/563) 0.48% (2/417) Male greater than 40 0.27% (2/754) 0.33% (2/614) Total 1.1% (30/2702) 0.28% (6/2139) Urogenital system: vaginal candidiasis, vaginitis, vaginosis fungal Skin: rash Hematologic: increased platelet count Frequency of less than 0.2% Other clinically-significant adverse reactions occurring in less than 0.2% of patients treated with KETEK from the controlled Phase 3 studies included: anxiety, bradycardia, eczema, elevated blood bilirubin, erythema multiforme, flushing, hypotension, increased blood alkaline phosphatase, increased eosinophil count, paresthesia, pruritus, urticaria. 6.2 Post-Marketing Experience The following adverse reactions have been identified during post-approval use of KETEK. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Allergic: face edema, severe allergic (hypersensitivity) reactions, including angioedema and anaphylaxis Cardiovascular: atrial arrhythmias, ventricular arrhythmias (including ventricular tachycardia and torsades de pointes) with potential fatal outcome, palpitation, ischemic cardiac events in the context of hypersensitivity reactions [see Warnings and Precautions (5.2)] Gastrointestinal system: pseudomembranous colitis, pancreatitis [see Warnings and Precautions (5.5] Liver and biliary system: Hepatic dysfunction, fulminant hepatitis, hepatic necrosis, and hepatic failure, chromaturia [see Contraindications (4.2); Warnings and Precautions (5.1)] Musculoskeletal: muscle cramps, arthralgia, myalgia, exacerbation of myasthenia gravis [see Contraindications (4.1)] Nervous system: loss of consciousness, in some cases associated with vagal syndrome, tremor, convulsions Psychiatric disorders: confusion, hallucinations (mostly visual) Special senses: taste/smell perversion and/or loss, hearing loss Respiratory, thoracic and mediastinal disorders: dyspnea

Drug Interactions

Telithromycin is a strong inhibitor of CYP3A4 and also a CYP3A4 substrate. Co-administration of KETEK and drugs that induce or inhibit the cytochrome P450 3A4 enzyme system may affect KETEK plasma concentrations resulting in diminished efficacy or an increase or prolongation of both the therapeutic and adverse effects; therefore, appropriate dosage adjustments may be necessary for drugs co-administered with telithromycin. Studies were performed to evaluate the effect of CYP3A4 inhibitors on telithromycin and the effect of telithromycin on drugs that are substrates of CYP3A4 and CYP2D6. In addition, drug interaction studies were conducted with several other concomitantly prescribed drugs. Table 3 summarizes both drugs with pharmacokinetics that are affected by KETEK as well as drugs that affect the pharmacokinetics of KETEK. Table 3: Clinically Significant Drug Interactions with KETEK Drugs That Are Affected By KETEK Drug(s) with Pharmacokinetics Affected by KETEK (Mechanism of interaction, if known) Recommendation (Exposure) Comments Cisapride (CYP3A4 Substrate) Contraindicated (Plasma exposure increased) Co-administration of cisapride with repeated doses of KETEK resulted in significant increases in QTc. [see Contraindications (4.4)] Pimozide (CYP3A4 Substrate) Contraindicated (Plasma exposure likely to be increased) Although there are no studies looking at the interaction between KETEK and pimozide, there is a potential risk of life-threatening QT prolongation. [see Contraindications (4.4)] Colchicine (CYP3A4 and P-glycoprotein efflux transporter Substrate) Contraindicated in patients with renal or hepatic impairment. (Plasma exposure increased) Risk of life-threatening colchicine toxicity. If co-administration of KETEK and colchicine is necessary in patients with normal renal and hepatic function, reduce the dose of colchicine. Monitor for symptoms of colchicine toxicity. [see Contraindications (4.5); Warnings and Precautions (5.5)] Simvastatin, Lovastatin, and Atorvastatin (HMG-CoA Reductase Inhibitors metabolized by CYP3A4) (CYP3A4 Substrate) Avoid Use (Plasma exposure increased) High levels of HMG-CoA reductase inhibitors increase the risk of myopathy and rhabdomyolysis. Avoid concomitant use of simvastatin, lovastatin, or atorvastatin with KETEK. If KETEK is prescribed, suspend therapy with simvastatin, lovastatin, or atorvastatin during the course of KETEK. An interaction may occur with simvastatin, lovastatin or atorvastatin but not with statins which are not metabolized by CYP3A4. [see Warnings and Precautions (5.5)] Ergot Alkaloids Not Recommended (Plasma exposure likely to be increased) No specific drug interaction studies have been performed. However, acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia has been reported when macrolide antibiotics were co-administered with ergot alkaloid derivatives (such as ergotamine or dihydroergotamine). Without further data, the co-administration of KETEK and these drugs is not recommended. Calcium Channel Blockers (CYP3A4 Substrate) Use with Caution (Plasma exposure increased) Hypotension, bradyarrhythmia, and loss of consciousness have been observed in patients receiving concomitant treatment with calcium channel blockers that are substrates of CYP3A4 (e.g., verapamil, amlodipine, diltiazem). Monitor for these adverse reactions and toxicity related to calcium channel blockers and adjust calcium channel blocker dosage as necessary. Midazolam (CYP3A4 Substrate) Use with Caution (Plasma exposure likely to be increased) Monitor for benzodiazepine-related adverse reactions and adjust midazolam dosage if necessary. Use caution with other benzodiazepines, which are metabolized by CYP3A4 and undergo a high first-pass effect (e.g., triazolam). Other drugs metabolized by CYP3A4, such as carbamazepine, cyclosporine, tacrolimus, sirolimus, hexobarbital, and phenytoin (CYP3A4 Substrates) Use with Caution (Plasma exposure likely to be increased) No specific drug interaction studies have been performed to evaluate these drug-drug interactions with KETEK. However, increases or prolongation of the therapeutic and/or adverse effects of drugs metabolized by the cytochrome P450 system may be observed if administered with KETEK. Metoprolol (CYP2D6 Substrate) Use with Caution (Plasma exposure increased) Co-administration of KETEK and metoprolol in patients with heart failure could lead to metoprolol toxicity and should be considered with caution. Monitor for metoprolol toxicity and adjust metoprolol dosage. Digoxin Use with Caution (Plasma exposure increased) Monitor for digoxin side effects or serum levels during concomitant administration of digoxin and KETEK. Theophylline Use with Caution (Plasma exposure minimally increased) Co-administration of theophylline may worsen gastrointestinal effects such as nausea and vomiting, especially in female patients. Administer theophylline and KETEK 1 hour apart to decrease the likelihood of gastrointestinal side effects. Oral Anticoagulants Use with Caution (Plasma exposure increased) Spontaneous post-marketing reports suggest that administration of KETEK and oral anticoagulants concomitantly may potentiate the effects of the oral anticoagulants. Consider monitoring prothrombin times/INR while patients are receiving KETEK and oral anticoagulants simultaneously. Drugs that Affect KETEK Drug(s) that Affect the Pharmacokinetics of KETEK Recommendation Comments Rifampin (CYP3A4 Inducer) Avoid Concomitant Use (Reduced KETEK exposure) Loss of KETEK effect is likely [see Clinical Pharmacology (12.3) ] Other CYP3A4 inducers (phenytoin, carbamazepine, or phenobarbital) Avoid Concomitant Use (Reduced KETEK exposure) Loss of KETEK effect is likely [see Clinical Pharmacology (12.3) ] Itraconazole and Ketoconazole Avoid Concomitant Use (Increased KETEK exposure) Increased KETEK toxicity is likely [see Clinical Pharmacology (12.3) ] CYP3A4 inducers: Decreased KETEK levels resulting in loss of efficacy. Avoid concomitant use. (7) CYP3A4 inhibitors: Increased KETEK levels and risk of adverse reactions. Avoid concomitant use. (7) Drugs metabolized via CYP3A4 pathway: KETEK may increase levels of these concomitant medications. Avoid concomitant use. If not possible, monitor for concomitant drug toxicity. Consider dosage reduction. (7)

Use In Specific Populations

The safety and effectiveness under the age of 18 years has not been established. (8.4) 8.1 Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Telithromycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Telithromycin was not teratogenic in the rat or rabbit. Reproduction studies have been performed in rats and rabbits, with effect on pre-post natal development studied in the rat. At doses of 150 and 20 mg/kg/day in rats and rabbits respectively (approximately 2 and 0.5 times the recommended clinical dose), no evidence of fetal terata was found. At doses higher than 150 or 20 mg/kg in rats and rabbits, respectively, maternal toxicity may have resulted in delayed fetal maturation. No adverse effects on prenatal and postnatal development of rat pups were observed at 125 mg/kg/day (1.5 times) the daily human dose. 8.3 Nursing Mothers Telithromycin is excreted in breast milk of rats. Telithromycin may also be excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when KETEK is administered to a nursing mother. 8.4 Pediatric Use The safety and effectiveness of KETEK in pediatric patients less than18 years of age has not been established. Pediatric clinical trials were halted prematurely due to concern of serious postmarketing hepatic adverse reactions observed in adults. [see Warnings and Precautions (5.1)] 8.5 Geriatric Use Of the total number of patients in Phase 3 clinical trials (n=4,780), KETEK was administered to 694 patients who were 65 years and older, including 231 patients who were 75 years and older. Efficacy and safety in patients 65 years and older were generally similar to that observed in younger patients; however, greater sensitivity of some older individuals cannot be ruled out. [see Clinical Pharmacology (12.3)] 8.6 Renal and/or Hepatic Impairment Dose adjustment is required in patients with severe renal impairment (CLCr less than 30 mL/min) or on dialysis. Further dose adjustment is required in patients with severe renal impairment and coexisting hepatic impairment. [see Dosage and Administration (2.2) ]

Always pay a fair price for your medication!

Our FREE Ketek discount card helps you save money on the exact same Ketek prescription you're already paying for. Print the card in seconds, then take it to your pharmacy the next time you get your Ketek prescription filled. Hand it to them and save between 10% - 85% off this prescription!

7 Great Reasons To Print Your Ketek Coupon Card Today

  • 100% FREE (no fees, ever)
  • Print and use immediately
  • Everyone qualifies
  • Easy To Use
  • No Paperwork
  • Unlimited uses and no expiration date
  • Accepted at over 63,000 pharmacies nationwide!

Save on the cost of your prescription with our free Ketek Discount Card

Be sure to ask your pharmacist not to substitute another card for ours as we are confident we offer the highest savings possible.

image description
SAVINGS OF 70%! "If you have a high deductible medical insurance (like me) or no insurance at all and you want to save money on your prescriptions, print a card. It's free and no personal information required. This card saved me $218.89 today on my prescription! It's unbelievable but it`s true. I am so grateful, for now I can actually afford my medication." Zarah
SAVINGS OF 70%! "Hi! Just want to say thanks to this website for providing a card such as this to the public for free! A few weeks ago I printed out one of your cards and used it on one of my medications because my co-pay went up and to my surprise instead of paying a $45.00 co-pay through my insurance, I ended up paying only $17.00 by just running it through the discount card! Now I will be comparing prices!" Steve
SAVINGS OF 70%! "I went to a chain pharmacy today and wanted to fill a prescription and not run it through my insurance.They quoted me $164.00 for a 90 day generic supply, I asked them to double check and it was the best they could do. I came home, checked your online price, registered and had a card in 15 seconds. Went back, and the prescription was $16.92!"
"FYI the pharmacist asked for the website and wants it to refer customers in store directly. I don’t quite understand how it works, but honestly, I don’t care how it works, it did!!!!"
Ivan S.
SAVINGS OF 70%! "Today I went to get a seizure Rx filled at the pharmacy for my daughter, Erica. The pharmacy told me it would be $230. I used your card and it cost me less than $28. Thank you so much." Melissa
SAVINGS OF 70%! "I needed an prescription eye drop last week. The cost was going to be $129. With your prescription savings card it cost $25! I’m telling everyone I know. Thanks!!" Monday M.
SAVINGS OF 70%! "When I first used my card, both the pharmacist and I were amazed! She took the information from it for herself and then compared the costs to what my prices would have been had I gone through my insurance (I had none at the time I 1st used my card), and I still saved a lot of money!! They entered the new info. into their system and in the meantime I`ve told lots of friends and family members about how to save.....THANK YOU SO VERY MUCH!!!!!" Elizabeth H.
SAVINGS OF 70%! "My beloved Border Collie - named Mickey - was recently diagnosed with a form of plasmacytoma cancer and is on both Melphalan and Prednisone drugs as part of his monthly treatment. I printed out the prescription savings card and took it to my local pharmacist. I was so pleasantly surprised to know that the card indeed will save us money! I was able to buy the Melphalan chemotherapy drug for $34 less than the last 2 months, since we started treatment! Thanks so much!" Mary L.
SAVINGS OF 70%! "Wow! I can`t believe this actually worked. I have no insurance at this time and have to pay
I lost my insurance coverage and went online seeking help and found this CARD! It worked and saved me money $$$$$ very 1st time. There are others out there but with less coverage and a smaller list of drugs or they charge you a monthly fee. I am so happy I take 3 prescriptions a month forever and at times more and I will save over 78% as I figured it out, and that is great tell everybody you know as I am doing."
David B.
SAVINGS OF 70%! "My husband and I lost our insurance. This is the card to use to save money. His blood pressure medicine is $55. I now can get it for $13.44. That is quite a difference!" Candace
SAVINGS OF 70%! "Thank you SO MUCH! My patients have saved so much money using these cards." Danielle <br/>Primary Care Coalition<br/>primarycarecoalition.org
SAVINGS OF 70%! "While I am blessed to be a Medicaid patient, I know plenty of people which could include me if I didn’t have Medicaid who rely heavily on the WalMart and Target $4 lists. After comparing prices on this and other sites I have seen that there is the greatest free drug card savings potential on this site. I have already printed out 3 cards for loved ones." Jacques M.
SAVINGS OF 70%! "I have been using the RX card for almost a year now. In that time, it has saved my family over $4000. We have no insurance, and the RX card has been a God send. My husband and I are both disabled, and my 65-year old mother is almost blind and diabetic, so we would have simply had to do without. The RX card enabled us to have the meds we need. Thank you so very much!" Sharon H.
SAVINGS OF 70%! "Today, on three different prescriptions, I saved over $70!!! Thank you so much." Susan

Talked about in

Accepted at over 63,000 pharmacies nationwide including:

Save up to 85% on your medication:

PRINT FREE CARD NOW